VPC
KNSA icon

Vestal Point Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vestal Point Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-169,864
Closed -$3.77M – 80
2025
Q1 		$3.77M Buy
+169,864
New +$3.5M 0.27% 48

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Vestal Point Capital's KNSA Position: Q2 2025 in Review

Vestal Point Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 169,864 shares — an estimated $3.77M sold.

Vestal Point Capital first reported a position in KNSA in Q1 2025 and held it in 1 quarter. The position peaked at $3.77M in Q1 2025. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • Vestal Point Capital reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 169,864 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $3.77M.
  • Vestal Point Capital first reported a position in Kiniksa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Vestal Point Capital's Kiniksa Pharmaceuticals position peaked at $3.77M in Q1 2025.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.